DSIP (Delta Sleep-Inducing Peptide): Research Overview

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Overview of Delta Sleep-Inducing Peptide

Delta sleep-inducing peptide (DSIP) is a biologically active nonapeptide first identified in 1974 by the Schoenenberger-Monnier group in Switzerland. It was originally isolated from the cerebral venous blood of rabbits during experimentally induced sleep.

Over subsequent decades, numerous studies have highlighted its involvement in sleep induction, neuroendocrine regulation, and modulation of stress and pain responses.

Physiological Actions

DSIP is synthesized in the hypothalamus and exerts effects on multiple brain regions, including the brainstem. It promotes sleep by enhancing delta-wave activity on the electroencephalogram (EEG). This has been consistently observed across species including rodents, cats, and humans.

Endogenous DSIP levels fluctuate in a circadian rhythm, with lower concentrations in the morning and elevated levels later in the day. Interestingly, increased DSIP levels have been linked to suppression of both slow-wave and rapid-eye-movement (REM) sleep, as well as changes in body temperature regulation.

Unlike many peptides, DSIP can cross the blood–brain barrier with relative ease and is also absorbed through the gastrointestinal tract without enzymatic degradation. High concentrations have been detected in human breast milk, raising questions about its potential influence on neonatal sleep regulation.

Broader Regulatory Roles

Experimental research has demonstrated that DSIP influences several aspects of endocrine and neurochemical balance. Findings include:

• Reduction of basal corticotropin levels
• Stimulation of luteinizing hormone release
• Modulation of somatoliberin and somatotropin secretion
• Interaction with monoamine oxidase activity
• Regulation of circadian locomotor activity

These effects highlight DSIP’s broad range of physiological functions beyond sleep promotion.

Distribution and Proposed Mechanisms

DSIP has been found in both free and bound forms in the hypothalamus, limbic system, and pituitary gland, and evidence suggests it activates hypothalamic pathways linked to luteinizing hormone release during sleep. Proposed mechanisms include interaction with delta-opioid and GABA-A receptors, both implicated in sleep regulation, and effects on serotonin and dopamine signaling.

In perifused rat pineal glands, DSIP stimulated secretion of melatonin, 5-methoxytryptophol, and serotonin, which may connect it to circadian regulation. DSIP has also been reported to shift levels of substance P, beta-endorphin, and cortisol, which may underlie its stress-protective activity in animal models.

Mitochondrial, Antioxidant and Systemic Effects

In rat brain mitochondria, DSIP influenced respiratory activity and showed stress-protective potency under experimental hypoxia. DSIP analogues have shown antioxidative and detoxifying effects in laboratory studies. Other preclinical reports describe effects on thermoregulation, including protection against hypothermia, on arterial pressure through vasodilation, and on T-lymphocyte and natural killer cell activity.

Findings from Published Studies

Insomnia Research

Multiple studies have evaluated DSIP in chronic insomnia:

• Study 1: Intravenous DSIP was compared with placebo across four nights in a crossover design. Findings indicated modest improvements in non-REM sleep and total sleep duration, though results were not clinically significant.
• Study 2: In a parallel-group trial with chronic insomniacs, DSIP administration led to increased sleep efficiency and reduced sleep latency. However, improvements were small and partly attributable to placebo variability.

Neurological Activity and Convulsions

Animal studies have revealed anticonvulsant properties of DSIP, including suppression of induced convulsive foci in the cerebral cortex and prevention of seizures in chemically provoked models. These effects appear linked to DSIP’s modulation of excitability within the substantia nigra.

Key Takeaways

Delta sleep-inducing peptide is a naturally occurring neuromodulator with demonstrated roles in sleep regulation, endocrine function, and neuroprotection.

Future investigations are required to establish consistent clinical applications and clarify its mechanisms across different physiological systems.

REFERENCES

1. Larbig, W., Gerber, W. D., Kluck, M., & Schoenenberger, G. A. (1984). Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. European neurology, 23(5), 372–385. https://doi.org/10.1159/000115716
2. Shandra, A. A., Godlevskii, L. S., Mazarati, A. M., Oleshko, A. A., & Mikhaleva, I. I. (1993). The influence of the delta-sleep-inducing peptide on convulsive activity. Neuroscience and behavioral physiology, 23(5), 480–485. https://doi.org/10.1007/BF01183011
3. Graf, M. V., & Kastin, A. J. (1986). Delta-sleep-inducing peptide (DSIP): an update. Peptides, 7(6), 1165–1187.
4. Khvatova, E. M., Samartzev, V. N., Zagoskin, P. P., Prudchenko, I. A., & Mikhaleva, I. I. (2003). Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides, 24(2), 307–311.
5. Ouichou A, Zitouni M, Raynaud F, Simonneaux V, Gharib A, Pévet P. Delta-sleep-inducing peptide stimulates melatonin, 5-methoxytryptophol and serotonin secretion from perifused rat pineal glands. Biol Signals. 1992;1(2):65-77. PMID: 1339175.
6. Mikhaleva II, Ivanov VT, Onoprienko LV, et al. Antioxidative and detoxifying effects of analogues of delta-sleep inducing peptide (DSIP). Bioorg Khim. 2014;40(1):3-11. PMID: 25898718.
7. Schneider-Helmert D. Effects of DSIP on narcolepsy. Eur Neurol. 1984;23(5):353-7. PMID: 6548968.

Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International journal of clinical pharmacology research, 7(2), 105–110.